Page 3 - Multiple Sclerosis Relapse News Today

The investigational evobrutinib, an Brutons tyrosine kinase inhibitor, showed favorable safety and efficacy in the longest trial to date of a drug in this class in patients with multiple sclerosis.

Patients with MS stable on natalizumab administered every 4 weeks may be able to safely switch to every-6-weeks dosing with no clinically meaningful loss of efficacy.

Data on repair or progression in normal-appearing brain tissue on conventional MRI.

In a randomized trial, depression improved compared to usual neurologist care.

Consumption of a ketogenic diet is safe — and may help reduce disability and improve fatigue and depressive symptoms in patients with relapsing multiple sclerosis (MS), new research suggests.

Serum neurofilament light chain and glial fibrillary acidic protein levels can help improve outcome predictions in multiple sclerosis — and are linked to relapse risk after treatment discontinuation.

Among patients with multiple sclerosis receiving assisted reproductive therapy, risk for relapse is increased only in those not treated with disease modifying therapy, new research suggests.

Spinal atrophy observed on MRI correlates with progression to secondary progressive MS when other signs may not be evident, new research shows.

Paramagnetic rim lesions on MRI show a high specificity for a diagnosis of multiple sclerosis; and higher numbers of the lesions are associated with worse disability, new research suggests.

Results from a network analysis could illuminate the mechanism of fatigue in multiple sclerosis and enable research into more effective treatments.